Opioid Therapy Articles & Analysis
10 news found
Key data highlights with the Evoke® System to include holistic composite treatment outcomes for disrupting the chronic pain cycle; opioid-sparing effects of therapy; real-world results; and cost-effectiveness compared to open-loop stimulation. Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field ...
DEA’s National Prescription Drug Take Back Day reflects DEA’s commitment to Americans’ safety and health, encouraging the public to remove unneeded medications from their homes as a measure of preventing medication misuse and opioid addiction from ever starting. The Berkshire team supports the DEA’s commitment to making communities safer and healthier. ...
The initial intended use for COPA will include the delivery of opioids for the treatment of chronic pain and the delivery of methadone in Medication Assisted Therapy for the treatment of opioid use disorder. ...
The Company intends to initially seek opportunities to leverage COPA in the delivery and remote management of controlled oral liquid medications for chronic pain and opioid addiction medication assisted therapy, as the Company believes they have the greatest need for the benefits of COPA’s features. ...
There is a high unmet medical need in chronic pain, particularly among patients with concomitant opioid use problems. If approved, Buvidal could become an important therapeutic option for the management of chronic pain, adding to the current indication of treating opioid dependence”, says Dr. ...
Three overarching features combine to make the COPA technology unique: security, compliance support (metrics) with remote monitoring and precise liquid dispensing. Chronic pain and opioid addiction medication assisted therapy have been identified as potential indications with the greatest need for the benefits of these features. ...
Three overarching features combine to make the COPA offering unique: security, compliance support (metrics) and precise liquid dispensing. Chronic pain and opioid addiction medication assisted therapy have been identified as potential indications with the greatest need for the benefits of these features. ...
With his help, the technology we're developing with Stevanato Group has great potential for application beyond our non-opioid BB106 therapy for pain management," said Jeffrey Becker, co-founder and CSO, Bexson Biomedical. "Sheldon's expertise and innovations are allowing us to explore additional psychedelic and non-psychedelic therapies to help ...
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable ...
Under the agreement, the parties will work together to obtain appropriate regulatory approvals and commercialize self-contained, infusible, non-opioid post-operative pain pharmaceutical product in the United States, Canada and Mexico. ...